Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and machine learning.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.03, representing a -1.57% change from its previous close.
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading.
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Officer and Chief Commercial Officer Ben Taylor - Chief Financial Officer Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning.
